Gland Pharma's JNPC facility completes USFDA inspection
The said inspection was concluded with THREE (3) Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content